Study could boost new Astra-Zeneca drug

A study published in the New England Journal of Medicine Sunday held some news for pharmaceutical giant Astra-Zeneca, finding that its Brilinta drug lowers death rates compared that of a competing product from its top rivals.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.